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The association between donor specific antibodies (DSA) and renal transplant rejection has been generally established, but there
are cases when a DSA is present without rejection. We examined 73 renal transplant recipients biopsied for transplant dysfunction
with DSA test results available: 23 patients diffusely positive for C4d (C4d+), 25 patients focally positive for C4d, and 25 patients
negative for C4d (C4d−). We performed C1q and IgG subclass testing in our DSA+ and C4d+ patient group. Graft outcomes were
determined for theC4d+ group. All 23 C4d+ patients had IgGDSAwith an average of 12,500MFI (cumulativeDSAMFI).TheC4d−
patients had average DSA less than 500MFI. Among the patients with C4d+ biopsies, 100% had IgGDSA, 70% had C1q+ DSA, and
83% had complement fixing IgG subclass antibodies. Interestingly, IgG4 was seen in 10 of the 23 recipients’ sera, but always along
with complement fixing IgG1, and we have previously seen excellent function in patients when IgG4 DSA exists alone. Cumulative
DSA above 10,000MFIwere associated with C4d deposition and complement fixation.There was no significant correlation between
graft loss and C1q positivity, and IgG subclass analysis seemed to be a better correlate for complement fixing antibodies in the C4d+
patient group.
1. Introduction
In Humoral Theory of Transplantation [1] Terasaki argued
against Sir Peter Medawar’s evidence for cellular rejection
through thymus directed T-cell immunity that had for
decades biased the transplantation community against anti-
bodies as a cause of transplant rejection and loss. Terasaki
first proposed a compelling hypothesis that linked anti-
bodies (particularly to human leukocyte antigens (HLA))
with occurrence of transplant rejection. Antibody rejection
was particularly associated with complement activation and
shown specifically by the deposition of C4d on the kidney
peritubular capillaries [2–4].
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Interestingly, Terasaki showed in his studies a significant
correlation of non-donor specific antibodies, HLA antibodies
with poor outcomes [5–7], and later revealed the specific
correlation of HLA donor specific antibodies (DSA) resulting
in poor outcomes, that is, a more rigorous proof of the
antibodies’ role in rejection.
During the early days circa 2000, the elution of anti-
bodies from rejected kidneys, biopsies, and C4d deposition
results showed that both Sir Peter Medawar and Terasaki
were correct. In several publications until the 1990s ([8]
histological review) allograft dysfunction was accounted for
by acute cellular rejection (ACR), and antibodies had a
minor role with the exception of hyperacute rejection [9, 10].
Antibody mediated rejection (AMR) assumed a prominent
role in allograft dysfunction and loss with the discovery of
the complement protein C4d on the peritubular capillaries
[2–4] and the principles described in Humoral Theory of
Transplantation [1]. In fact, the association of antibodies was
clearly shown by histologic and antibody examination of
232 transplant recipients, 67 undergoing acute dysfunction.
In this study, 30% of the patients showed AMR only, 45%
exhibited AMR plus cell mediated rejection (CMR), 15%
CMR only, and only 10% acute tubular necrosis [11]. Clearly
this data shows 75% of the patients had AMR. It is notable
that antibody class switch from IgM to IgG is under the
modulation of T-helper cells. Therefore, one can conclude
that the T-cells are indirectly identified with AMR, and,
of course, 60% of the group studied also had diagnosed
CMR. Since AMR has been shown to be the prevalent
component in graft rejection and loss, immunosuppressant
drugs for AMRhave become one of themost unmet needs for
treatment. Graft rejection is currently controlled primarily
by increasing T-cell immunosuppression, which one could
argue is a good AMR immunosuppressant because of T-
helper cell function in antibody formation. Albeit Rituximab,
IVIg, Atgam, and Bortezomib seem to have an effect on B-
cells and/or antibodies, there is no good plasma cell-targeting
immunosuppressant agent.
With the discussion above as background,we have chosen
to study antibody mediated rejection in a patient population
that had allograft dysfunction with primary focus on C4d
positive/DSA positive (C4d+ DSA+) patients. Our patient
groups were long term graft survivors and had an average of
>7 years after transplant at the time of dysfunction, biopsy,
and DSA analysis. We examined 73 transplant recipients
biopsied for transplant dysfunction, whereof 23 of these
patients were diffusely positive for C4d (C4d+), 25 patients
were focally positive for C4d, and 25 patients tested negative
for C4d (C4d−). DSA test results for these patients were
available within 1–10 days of the biopsy. In order to compare
DSA and C4d results, we performed C1q and IgG subclass
testing in our DSA+ and C4d+ patient group. Graft outcomes
were determined for the C4d+ group. The antibody strength
was ascertained by measurement of the mean fluorescence
intensity (MFI) in the various tests.
Although there are commercially available kits for iden-
tifying C1q-binding HLA antibodies, IgG subclasses of HLA
antibodies were measured by using several murine antibody
clones recognizing human IgG subclasses. These clones have
been tested by several other investigators with variable
outcomes and correlations to the different subclasses [12–15].
In our hands, these clones behave differentially depending on
the dilution tested andwhether theywere deployed in a direct
or sandwich assay. Cross-reactivity was a major issue for us,
whereas in other articles either cross-reactivity of clones was
not determined [12, 13] or clones were described to be specific
with minimal cross-reactivity [14, 15]. We primarily assessed
the IgG subclasses using direct labeling. However, data is
presented that suggests indirect “sandwich” assays could give
a more specific result.
2. Material and Methods
2.1. Study Patients. Seventy-three renal transplant recipi-
ents (Table 1) were biopsied for cause and analyzed by
immunofluorescence for C4d deposition in the peritubular
capillaries (PTC) from frozenmaterial. Twenty-three patients
were diffusely positive (>50% PTC staining), 25 focally
positive (20–50% PTC staining), and 25 negative (<20% PTC
staining).Thepatients were chosen sequentially and reviewed
retrospectively, with the requirement that aDSA test had been
performed within ten days of the biopsy. All data review and
study testing were performed under IRB approval.
2.2. C4d Immunostaining. Biopsied renal tissue was placed
in Zeus fixative (Zeus Scientific, Branchburg, NJ), sectioned
using a cryostat, and then stained as follows in a multistep
procedure. Initially, the Zeus-fixed tissue was placed in Zeus
fixative wash solution (Zeus Scientific) and sectioned in a
cryostat at 4𝜇m thickness, and the resultant sections were
placed on poly-L-lysine-coated slides at room temperature,
allowed to dry, and then fixed in cold acetone for 10 minutes.
The tissue sections were then washed in PBS times 3 for
10 minutes each. The sections were then stained using a
3-step procedure as follows: (1) mouse anti-human C4d
(Quidel Corp., San Diego, CA) was diluted 1 : 200, for 30
minutes and then washed in PBS; (2) FITC-conjugated rabbit
anti-mouse immunoglobulin (Dako Corp, Carpinteria, CA)
diluted 1 : 30, for 20 minutes, with interval wash in PBS; and
(3) finally FITC-conjugated swine anti-rabbit immunoglob-
ulin (Dako Corp), diluted 1 : 30, for 20 minutes, with final
wash in PBS. Slides were then mounted with a cover slip in
glycerol/Optimax solution and reviewed in an Olympus BX
Fluorescence Microscope.
2.3. HLA Typing. HLA Class I & II antigens were detected
using the standard monoclonal trays using the microcy-
totoxicity method (One Lambda, Inc., Canoga Park, CA).
In the case of ambiguous results or uncertainty, additional
testing using PCR-SSP was performed (One Lambda, Inc.)
and (QIAGEN Inc., Valencia, CA).
2.4. HLA Single Antigen Bead (SAB) Specificity Analysis.
All patients were tested for the presence of antibodies of
IgG isotype using SAB Luminex technology (LABScreen
Single Antigen, One Lambda, Inc.).The tests were performed
according to the vendor’s instructions using DTT-treated
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Table 1: Patient demographics.
C4d diffusely positive
(𝑁 = 23)
C4d focally positive
(𝑁 = 25)
C4d negative
(𝑁 = 25) 𝑃 value
Age
At biopsy [yr.] 44.5 ± 12.7 45.7 ± 9.9 49.5 ± 13.7 0.343
At transplantation [yr.] 39.0 ± 10.9 37.1 ± 12.1 42.1 ± 13.3 0.356
Female sex [%] 7 (30.4) 8 (32.0) 8 (32.0) 0.938
Race or ethnic group [%] 0.104
White Hispanic 15 (65.2) 11 (44.0) 16 (64.0)
Asian 2 (8.7) 4 (16.0) 2 (8.0)
Black non-Hispanic 4 (17.4) 1 (4.0) 1 (4.0)
Mixed 0 (0.0) 4 (16.0) 0 (0.0)
White non-Hispanic 3 (13.0) 2 (8.0) 5 (20.0)
White unknown 0 (0.0) 1 (4.0) 0 (0.0)
Native American 0 (0.0) 1 (4.0) 0 (0.0)
Previous Transplantation [%] 7 (30.4) 2 (8.0) 4 (16.0) 0.168
Simultaneous kidney pancreas [%] 1 (4.3) 3 (12.0) 1 (4.0) 0.423
Deceased donor [%] 15 (65.2) 20 (80.0) 19 (76.0) 0.211
Cause of ESRD [%] 0.868
Diabetes 4 (17.4) 4 (16.0) 7 (28.0)
Hypertension 8 (34.8) 7 (28.0) 7 (28.0)
Miscellaneous 9 (39.1) 10 (40.0) 9 (36.0)
Unknown 3 (13.0) 3 (12.0) 1 (4.0)
Allograft year at Bx [yr.] 5.4 ± 5.0 8.7 ± 6.2 7.4 ± 5.6 0.138
Allograft loss [%] 9 (39.1) 16 (64.0) 7 (28.0) 0.023
Graft year at loss [yr.] 7.8 ± 3.1 11.1 ± 7.0 10.9 ± 6.0 0.61
sera. Antibody specificity was analyzed manually using base-
line mean fluorescent intensity (MFI) values. Positive MFI
thresholds were defined on the basis of >500 MFI when a
DSA was noted for a donor mismatched HLA antigen.
2.5. IgG Subclass Determination. SAB Luminex technology
was used to determine the specificity of HLA Class I &
II IgG antibody subclasses. The “direct” subclass assay was
performed essentially in the manner of the standard SAB
assay, with the replacement of the PE-labeled polyclonal
goat anti-human IgG antibody with a PE-labeledmonoclonal
murine anti-human IgG subclass-specific antibody. DTT-
treated graft recipient serum was reacted with SAB for
30min, washed four times with 1x wash buffer, incubated
with PE-labeled subclass-specific monoclonal antibody for
30min, and washed twice before acquisition. The “sandwich
assay” was performed with an unlabeled subclass-specific
antibody and a PE-labeled secondary antibody. DTT-treated
graft recipient serum was reacted with SAB for 30min,
washed four timeswith 1xwash buffer, incubatedwithmurine
antihuman IgG subclass-specific monoclonal antibodies for
30min, washed four times, incubated with a polyclonal anti-
murine IgG-PE conjugate for 30min, and washed twice
before acquisition. The antibodies used for the direct assay
were purchased from Southern Biotech (Birmingham, AL)
and are detailed in Table 2. The antibodies used for the sand-
wich assay were unlabeled murine monoclonal antibodies
specific for human G1 (Clone HP6001, Millipore, Billerica,
MA), G2 (Clone HP6002, Millipore), G3 (Clone HP6047,
Alpha Diagnostic Intl. Inc., San Antonio, TX), and G4 (Clone
HP6023, Millipore) subclasses and a goat polyclonal F(ab)2
anti-murine IgG-PE conjugate (R &D Systems, Minneapolis,
MN). Positive control beads were produced by Acuimmune
(Chatsworth, CA) using IgG1–IgG4 and IgM purified from
myeloma plasma (Sigma-Aldrich, Saint Louis, MO) and
coupled to Microplex Microspheres (Luminex, Austin, TX).
Antibody specificity was analyzed manually using baseline
mean fluorescent intensity (MFI) values. PositiveMFI thresh-
olds were defined on the basis of >500 MFI when a DSA was
noted for a donor mismatched HLA antigen.
2.6. C1q SAB Specificity Analysis. C1q testing was per-
formed using the commercially available kit (C1qScreen, One
Lambda, Inc.) according to the manufacturer’s instructions.
Antibody specificity was analyzed manually using baseline
mean fluorescent intensity (MFI) values. PositiveMFI thresh-
olds were defined on the basis of >500 MFI when a DSA was
noted for a donor mismatched HLA antigen.
2.7. Statistical Analysis. Statistical analysis was performed
using Fishers 𝑇-test and/or ANOVA. Allograft survival was
analyzed using Kaplan Meier curves and the log-rank test.
3. Results and Discussion
IgG subclass analysis and how it is determined is a critical
issue with regard to the interpretation of complement fixing
4 Journal of Immunology Research
Table 2: PE conjugated secondary antibodies for IgG subclass detection.
Secondary Ab MFI [relative%]
IgG1 bead IgG2 bead IgG3 bead IgG4 bead IgM bead
IgG1-PE
1 𝜇g/mL HP6001 9989 (100) 341 (3) 27 (0) 3733 (37) 1814 (18)
IgG2-PE
5 𝜇g/mL HP6014 31 (0) 11621 (100) 576 (5) 117 (1) 556 (5)
IgG3-PE
5 𝜇g/mL HP6050 19 (0) 21 (0) 10666 (100) 307 (3) 215 (2)
IgG4-PE
1 𝜇g/mL HP6023 5 (0) 113 (0) 12 (0) 28872 (100) 50 (0)
and noncomplement fixing antibodies. We will endeavor
herein to explicate the best way to determine the IgG sub-
classes of HLA antibodies. In the literature [12–15] compar-
ative results for the IgG1 and IgG2 subclasses as correlate to
outcomes should be viewed in the context of cross-reactivity.
Therefore, in our results we present methodology for IgG
subclass analysis.
Our data represent a unique group of patients with an
average of greater than seven years of renal allograft function
at the time of biopsy and DSA determination. Therefore it
should be interpreted in this context.
The demographics of the studied patients are depicted in
Table 1. There is a significant correlation to graft loss of the
C4d+ and focally positive transplant recipients compared to
the C4d− patients when analyzed by ANOVA (Table 1), but
comparison of allograft survival among the groups did not
reach significance using Kaplan Meier curves and the log-
rank test (Figure 1). As noted, the average time of biopsy was
greater than seven years after transplant, and some of these
patients had incidences of rejection prior to inclusion in this
study.
The murine antibody clones that were utilized in the
subclass experiments at concentrations selected to minimize
cross-reactivity are shown in Figure 2 and Table 2. IgG1
had significant binding to the IgG4 control bead at the
concentration at 1𝜇g. These murine antibody clones were
chosen from the available clones binding to the subclasses
and represented the least cross-reactivity seen. The murine
monoclonal subclass clones were the same as used in most
of the subclass papers (Table 3) with the notable exception
of IgG4 HP6023, which showed a strong MFI and was
monospecific for IgG4. The concentration of IgG1 used by
most of the investigators was different than used by us, and
it is worth observing that individual lots of HP6001 can be
quite different in cross-reactivity. Hence, it is problematic
when switching lots, and IgG1 could give false reading for
IgG4. In fact, Figure 3 shows the hypervariability of the
murine monoclonal antibodies to IgG subclasses with three
different sera on the control beads. As examples, Serum 1
shows results similar to that found in the PBS. Sera 2 and
3 show the extreme variation one finds with background
in different sera. IgG3 and IgG4 showed the least serum-
dependent differences. We point to these results as a caution
in the interpretation of not only our results but those given by
others, particularly for IgG1 and IgG2 and their propensity for
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Figure 1: Comparison of renal allograft survival among study
patients. The three cohorts of patients are separated according
to the results of their with renal biopsies: diffusely positive C4d
immunostaining (Positive), focally positive C4d immunostaining
(Focal), and negative C4d immunostaining (Negative).The log-rank
test result for the Kaplan Meier curves is 0.163.
cross-reactive results.We interpreted different serumbinding
results (Table 2) as nonspecific binding causing spurious
results in the direct binding assay. However, in preliminary
results when we used the indirect or “sandwich” assay at least
some of the cross-reactivity could be eliminated (Table 4).
We attribute the better results with the sandwich assay to the
increased washing and secondary antibody binding, which
we postulate caused elimination of lower affinity nonspecific
adsorbed serum proteins causing cross-reactivity. Although
our results below are based on the direct assay, we propose
that the indirect assay provides better discrimination of IgG
subclasses.
Table 5 shows a comparison of the cumulative DSA MFI
in the patients, stratified by C4d status. In the C4d+ patients,
all had DSA, and the average cumulative MFI was 12,353,
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Table 3: Reported IgG subclass antibodies used for DSA detection.
IgG1 IgG2 IgG3 IgG4 Control
Cicciarelli et
al. (2013) [16]
Clones HP6001 HP6014 HP6050 HP6023
Control beadConcentration 1𝜇g/mL 5𝜇g/mL 5 𝜇g/mL 1 𝜇g/mL
MFI
Lefaucheur et
al. (2016) [17]
Clones HP6001 31-7-4 HP6050 HP6025
Negative seraConcentration 5𝜇g/mL 5𝜇g/mL 20𝜇g/mL 20𝜇g/mL
MFI Mean Pan-IgG 1784
Ho¨nger et al.
(2011) [14]
Clones HP6001 31-7-4 HP6050 HP6025
Negative seraConcentration 1.3𝜇g/mL 1.3𝜇g/mL 10.6𝜇g/mL 0.68 𝜇g/mL
MFI Median, 1524; range, 1083–3584, ratio above the cutoff(i.e., ratio = MFI IgG subclass divided by MFI cutoff)
Kaneku et al.
(2012) [15]
Clones 4E3 HP6002 HP6050 HP6025
Control beadConcentration ? ? ? ?
MFI Median IgG subclass MFI in chronicrejection patients with post-OLT DSA (71%) was 5596
Khovanova et
al. (2015) [13]
Lowe et al.
(2013) [18]
Clones 4E3 31-7-4 HP6050 HP6025
Control bead
Concentration 250𝜇g/mL 250 𝜇g/mL 250 𝜇g/mL 250 𝜇g/mL
MFI Median MFI of IgG ∼1000
Arnold et al.
(2014) [12]
Clones HP6001 31-7-4 HP6050 HP6025
Isotype controlConcentration ? ? ? ?
MFI ? ? ? ?
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Figure 2: PE-conjugated secondary antibodies for IgG subclass detection. The control beads were incubated with negative control serum,
washed, and then detected with subclass-specific antibodies ((a): IgG1-PE; (b): IgG2-PE; (c): IgG3-PE; (d): IgG4-PE).
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Figure 3: Continued.
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Figure 3: Examples of serum-dependent cross-reactivity of IgG subclass detection on control beads. The control beads were incubated with
different patient sera, washed, and then detected with subclass-specific secondary antibodies ((a): patient serum 1; (b): patient serum 2; (c):
patient serum 3).
Table 4: Comparison of direct and sandwich IgG subclass assays.
IgG1 beads IgG2 beads IgG3 beads IgG4 beads IgM beads
Sandwich assay
IgG1
HP6001 100% 14% 41% 15% 2%
IgG2
HP6002 8% 100% 27% 25% 2%
IgG3
HP6047 1% 0% 100% 4% 0%
IgG4
HP6023 1% 1% 5% 100% 0%
Direct assay
IgG1
4E3 100% 228% 260% 5% 1%
IgG1
HP6001 100% 2% 88% 3% 1%
IgG2
HP6002 5% 100% 105% 126% 6%
IgG2
31-7-4 14% 100% 245% 185% 2%
IgG3
HP6050 0% 0% 100% 1% 0%
IgG4
HP6023 0% 0% 2% 100% 0%
8 Journal of Immunology Research
Table 5: Reactivity ofmonoclonal IgG subclass detection antibodies
against control microbeads.
C4d+ meanMFI C4d focallypositive mean MFI C4d−meanMFI
Total 12,353 4,771 963
Class I 5,487 443 442
Class II 7,373 4,317 520
MFI cutoff for DSA positivity set at 500.
as compared to the focally positive group average, which
was 4,771 MFI. The predominant HLA for C4d+ patients
was HLA Class II and also for the focally positive patients.
However, in the focally positive group, nearly all of the DSA
specificities were against HLA Class II and almost none
against HLA Class I. The C4d− group had very low average
DSA. One could argue that C4d− groups were potentially
subclinical rejection, but it was clear from our results that in
order to see C4d deposition on the PTC an average DSA of
greater than 10,000 MFI was needed.
A more in depth analysis of DSA and C4d groups is
presented in Table 6. All of the C4d positive groups were
significantly positive when compared to the C4d−, and C4d+
DSA was significant when compared to the DSA in the
focally positive group. This indicated that C4d reactivity was
a function of the DSA at a certain threshold level. DSA used
alone would predict a C4d+ result with a 95% confidence
limit range between 6,436 and 16,343 MFI. C4d+ compared
to focally positive C4d was significantly different, indicating
that the DSA associated with C4d+ biopsies had significantly
higher MFI. In addition, when we compared HLA Class I
to HLA Class II in the focally positive group there was a
significant difference, since the average HLA Class I DSA
associated with the focally positive recipients were below
500 MFI. However, when HLA Class II DSA were compared
between C4d+ and focally positive groups, there was no
significant difference. Therefore, we saw that focally positive
C4d and C4d+ were both associated with HLA Class II
DSA but only C4d+ had a significant correlation to DSA in
HLA Class I. Even though the focally positive C4d group
tended had positive HLA Class II, it was only just significant
compared to the C4d− with a broad 95% confidence limit
range (351–7,716 MFI).
Table 7 shows standard DSA specificities, IgG subclass,
and C1q all listed with MFI for the C4d+ patients. These
results reiterate the specific antibodies that we saw in the
analysis and the specific correlation of the results where there
appears to be a threshold DSA for the C1q positive reaction.
Also, one should note that the IgG subclass analysis seems to
give more complete information regarding the complement
fixing antibodies and IgG class switching. All of the patients
had standard DSA, whereas seven patients had no C1q DSA,
and this observation carries over into the total numbers of
DSA for both HLA Class I and II. That is, fifteen patients had
standard DSA to both Class I and Class II and only one class
of C1q DSA. The threshold of DSA before seeing the C1q+
reactivity was ∼4 DSA at 12,485 MFI and the C1q+ averaged
16,729 MFI with an average of only a single DSA (Table 8).
When we looked at the C4d+ patients outcomes there
was no significant correlationwith C1q or IgG subclass results
(Table 9). There seemed to be a trend toward increased graft
loss and thus possibly severity of rejection in the patients with
C1q+ DSA. The profile of rejection and loss was in general
a mixed, nonsignificant correlation. Looking at the pattern
of C1q and IgG subclass DSA among the C4d+ patients
(Table 10), we saw that all patients with complement fixing
IgG1 subclass hadDSA and eleven had IgG4 subclass. Also, 19
of 23 patients who were C4d+/DSA+ had complement fixing
subclass DSA, as compared to 16 of 23 with C1q+ DSA. In
this analysis, IgG1 subclass provided the best indication of
the C4d+ reactivity, but was not a significant predictor of
graft loss (Table 9). IgG4 subclass seemed to have little to
do with the outcome and the complement fixation; that is,
there was no blocking of the C4d+ complement fixation. An
interesting result was the absence of IgG1 at the time of biopsy
in four patients with significant dysfunction (average sCr of
4.4mg/dL). Although only one of the four lost the transplant,
it would be expected that there would be complement fixing
antibodies. However, as noted above, the IgG1 assay could
give quite variable results.
The absence of IgG3 subclass for the most part was likely
a function of our longer term transplant patients that were
analyzed. Also, patients had a large variation with regard
to the cross-reactive of the IgG subclasses owing to the
unknown variations intrinsically associated with the sera
(Figure 2).
4. Conclusions
Many articles have been written regarding de novo DSA early
after transplant [19–24]. The incidence of these de novo DSA
ranged from 10 to 30% and the studies included 1–5 year
follow-ups. In our study, a group of 73 patients were biopsied
for cause with an average of greater than seven years after
transplant, and the incidence of DSAwas 41%. It is reasonable
to suspect that patients biopsied for causewould have a higher
incidence of DSA than patients without cause for biopsy. One
should note that this is much less than has been reported
by investigators using histology C4d criteria [11], but these
patients likely exhibited accelerated acute rejection. However,
41% of patients with HLA DSA biopsied for cause can stand
alone as a unique observation for our groups of patients
biopsied after an average of seven years after transplant.There
is a paucity in the literature of correlates between C4d+ and
DSAMFI ranges but a few references show that immediately
after transplant if DSA increase sharply or are greater than
9,500MFI outcomes are significantly worse [20, 22]. A recent
article reported on the diagnostic contribution of various
assays to the diagnosis of silent AMR in renal transplant
recipients [25]. This prospective study included patients who
were determined to be DSA positive by protocol screening
andunderwent renal allograft biopsy, somewhat distinct from
our patients who exhibited allograft dysfunction and were
biopsied and tested for cause. The assays analyzed included
the standard SAB assay, the C1q SAB assay, and a C3d SAB
assay. The authors concluded that higher MFI DSA were
associated with higher risk for rejection or allograft loss, but
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Table 6: In depth analysis of DSA and C4d+, C4d focally positive, and C4d− patient groups.
𝑃 value 95% confidence interval MFI
C4d+ DSAMFI versus C4d− DSAMFI <0.0001 6,436–16,343
Class I C4d+ DSA MFI versus Class I C4d− DSAMFI <0.0005 2,473–7,616
Class II C4d+ DSA MFI versus Class II C4d− DSAMFI <0.0011 3,053–10,652
C4d+ DSAMFI versus C4d focally positive DSA MFI <0.012 1,718–13,443
Class I C4d+ DSA MFI versus Class I C4d focally positive DSA MFI <0.0005 2,455–7,634
Class II C4d+ DSAMFI versus Class II C4d focally positive DSAMFI <0.2 NS
Class I C4d focally positive DSA MFI versus Class I C4d− DSAMFI <0.4 NS
Class II C4d focally positive DSAMFI versus Class II C4d− DSAMFI <0.0431 351–7,716
that the addition of complement fixing assays did not provide
an enhanced diagnostic benefit. These results are concordant
with our own findings, despite the differences in patient
populations and utilized assays.
Our data show that the DSA in C4d+ patients was greater
than 12,000 MFI, composed of both HLA Class I and II, and
was significantly associated with C4d+ AMR. Also, focally
positive patients had predominantly HLA Class II with an
average of HLA Class I less than the 500 MFI negative cutoff
(a consequence of the number of patients with no Class I
DSA at all). Our observations showed that when C4d was
focally positive there was dysfunction significantly associated
only withHLAClass II. Others have shown thatmismatching
HLA Class II resulted in HLA-DQ DSA antibodies [26].
Certainly there may be occurrences where the DSA is lower
but significant ACR glomerulopathy is present. However, for
our C4d− group, the MFI range averaged just slightly above
our negative cutoff of 500 MFI. Part and parcel of the C4d+
deposition on the PTC is the DSA detected in the serum
but when one looks for antibodies on the PTC they are not
present [27].This may be a capping and stripping occurrence
[28]. However, the important point may be that serum DSA
ismore stable and indicative of glomerulopathy and therefore
suggests more attention be paid to DSA occurrence versus
C4d. The question remains as to the quantity and the quality
of the DSA present. In our study we have endeavored to
quantify the DSA and also measure the complement activity
of the antibodies. The measure of the complement inhibitory
factors (CD55, CD45, and CD35) has yet to quantified but
CD59 has been found on the PTC, thus inhibiting comple-
ment activity [29]. Again, this suggests that not just C4d but
the quantity and quality of DSA are in general overarching
factors in glomerulopathy.
Complement has a multitude of functions which include
death of target cell or organism, proinflammatory effects,
histamine release, phagocytosis, and chemotaxis [30, 31].
Therefore, looking for the activation of the complement
pathway, assays have been developed that show activation of
C1q as the initiation target which occurs when an antibody of
the complement fixing class (IgM, IgG 1, 3) binds to the target
HLA epitopes.TheC1q assay should give a good concordance
for with presence of damaging antibodies. Several authors
have shown the effect C1q binding assay as a positive
predictor of graft loss in de novo antibody patients, in both
renal and heart transplants [32, 33]. However, there is a DSA
threshold below which the C1q assay is negative, suggesting
the quantity of the DSA antibody gives rise to the C1q+ result
and the DSA MFI has the best predictive value for the C1q
test. In our experience, C1q was negative in 30% of the DSA
and C4d positive patients. Conversely, when complement
fixing antibody subclasses were measured directly only 18%
were negative. Furthermore, whenC1qwas positive, DSAwas
greater than 12,000 MFI and always appeared in the presence
of C4d+ DSA+ plus complement fixing subclass antibodies.
Among our patients who tested negative for C1q DSA, there
were three patients who had complement fixing IgG subclass
antibodies in the presence of DSA and C4d+ results.
IgG subclasses as mentioned above were a better correlate
for complement fixation compared to C1q in the C4d+ DSA
patients. We feel that IgG subclasses give a more complete
picture of the complement fixing antibodies present. Indeed,
strong complement fixing IgG3 along with DSA had the
highest risk for graft loss in liver transplant recipients [34].
C1q+ correlated with high risk of graft loss but seemed
to add little to the risk associated with IgG3+, DSA+. In
our current study, there was a paucity of IgG3+ recipients,
possibly owing to the average posttransplant biopsy times.
That is, IGg3 is the first complement fixing antibody in class
switching from IgM and may not be present except in acute,
initial AMR response which is in contrast with our greater
than seven years posttransplant, biopsied patient population.
Interestingly, in the 82% of patients IgG1+ C4d+, eleven
patients had antibodies of the IgG4 subclass, which is one
of the last antibodies to class switch. IgG4 has been often
described as a blocking antibody, because it does not fix
complement. IgG4 has been found in some patients to be
present solely and with salutary effect for transplantation
[16]. However, in this study we could not see any association
between the presence of IgG4 DSA and lower sCr or better
graft survival. One study suggests that IgG4 has a detrimental
effect on graft outcomes [35]. We suggest because class
switching is governed by time and T regulatory cells [36],
when IgG4 occurs in these long term biopsied patients it
may be associated with accommodation and T regulatory cell
but concomitant presence of IgG1 negates these beneficial
effects. In a recent case [37], we found a patient C4d− DSA+
C1q+ IgG1+ and IgG4+ (22,000 MFI) and a sCr < 0.9mg/dL.
The patient was treated for rejection with IVIg, but this
therapy was discontinued because of infusion reactions. In
this case, it is possible that the IgG4 antibody was blocking
10 Journal of Immunology Research
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Table 8: DSA, IgG subclasses, and C1q detection in C4d+ patients.
Assay Type of DSA detected [# of patients]
No DSA Class I only Class II only Class I+II
Standard 0 5 3 15
C1q 7 6 9 1
Assay Mean total DSA MFI Average # of DSA
Class II only Class I+II
Standard 7,046 8,320 12,485 4
C1q 14,460 17,864 16,729 1
Table 9: Analysis of C1q, IgG subclass, and Cd4d+ DSA.
C1q−
(𝑁 = 7)
C1q+
(𝑁 = 16)
IgG1−
(𝑁 = 4)
IgG1+
(𝑁 = 19)
IgG1+ IgG4−
(𝑁 = 8)
IgG1+ IgG4+
(𝑁 = 11)
Mean sCr
(at biopsy) 3.5mg/dL 2.9mg/dL 4.4mg/dL 2.8mg/dL 2.7mg/dL 2.9mg/dL
Mean sCr
(most recent) 2.2mg/dL 1.9mg/dL 3.4mg/dL 1.9mg/dL 1.8mg/dL 1.9mg/dL
Graft loss
(𝑁 = 5) 1 (14%) 4 (25%) 1 (25%) 4 (21%) 1 (13%) 3 (27%)
Values did not reach statistical significance.
Table 10: DSA detected by C1q and IgG subclass.
Patient C1q IgG1 IgG2 IgG3 IgG4
1 + + + +
2 +
3 +
4 + +
5 + + +
6 + +
7 + + +
8 + + + +
9 + +
10 +
11 + + +
12 + +
13 + + + +
14 + + +
15 + + + +
16
17 + + + +
18 + + + + +
19 + + +
20 +
21 + + + +
22
23 + + +
the complement fixation in vivo. Indeed we could show
CDC blocking by this patient’s serum in vitro in preliminary
experiments using human serum as a complement source
(unpublished data). Thus, if an IgG4 antibody is present
in high enough concentration we expect that the cross-
linking of two immunoglobulin molecules is blocked and
complement is not activated. Such a mechanism may not
occur in the C1q bead assay because of the quantity and
proximity of the HLA bound to the beads.
The presence of IgG4 in transplant recipientsmay bemost
analogous to the phenomenon observed in subcutaneous
allergic desensitization. Allergic desensitization occurs after
weekly subcutaneous allergen injection and successful results
show IgG4 specific allergen antibodies. The class switching
is governed by T regulatory cells secreting IL-10 and TGF-
𝛽 predominantly [36]. Thus the allograft may in many cases,
when DSA is present, eventually cause the switch to IgG4
and a T regulatory phase. However, it may be too late for
the allograft since the ongoing presence of complement fixing
antibodies typically precedes IgG4. We have proposed using
the allergic desensitization model in pretransplant patients
with high cPRA using HLA proteins specific to the detected
antibodies [16].
Lastly, IgG1 and IgG2 subclasses have a very high vari-
ability regarding their cross-reactivity when detected by the
available murine antibodies (Table 4). Although in this study
we used the direct assay for subclass identification, we have
seen less cross-reactivity using an indirect sandwich assay.
We postulate that the extra washing and additional antibody
strip off the lower affinity cross reacting antibodies. We
feel utilization of a standard indirect assay technique can
bring about a better correlation to the complement fixing
antibodies and aid in our understanding of the presence
or absence of subclass antibodies using standardized kits to
ascertain IgG subclass values.
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